Prospect: Information for the Patient
Gamavan 360micrograms/mL oral solution
(desmopressin)
Read this prospect carefully before starting to take this medication, as it contains important information for you.
1.What is Gamavan 360micrograms/mL oral solution and what it is used for
2.What you need to know before starting to take Gamavan 360micrograms/mL oral solution
3.How to take Gamavan 360micrograms/mL oral solution
4.Possible adverse effects
5.Storage of Gamavan 360micrograms/mL oral solution
6.Contents of the package and additional information
The active ingredient of this medication is called desmopresina. Desmopresina is very similar to a substance that is produced naturally in the body (the hypophyseal hormone vasopresina), which temporarily reduces the amount of urine produced by the body. This medication is intended for oral use only.
Desmopresina is used to treat:
Do not take Gamavan:
Warnings and precautions
Consult your doctor or pharmacist before starting to take Gamavan.
When taking desmopressin, avoid excessive fluid intake as it may cause fluid retention in the body and/or a decrease in sodium levels in the blood, with or without side effects (see section4. Possible side effects).
Special care should be taken with desmopressin to avoid fluid retention in the body and a decrease in sodium levels in the blood in the following cases:
Other medications and Gamavan
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medication, especially:
These medications increase the risk of fluid retention, which dilutes the salt in the body.
Taking Gamavan with food and drinks
See section3 “How to take”.
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.
It is preferable to avoid taking Gamavan during pregnancy.
Desmopressin passes into breast milk. If you are being treated with desmopressin, you should stop breastfeeding.
Driving and operating machinery
Gamavan does not affect the ability to drive or operate machinery.
Important information about some of the components of Gamavan:
This medication may cause allergic reactions (possibly delayed) because it contains methyl-parahydroxybenzoate sodium and propyl-parahydroxybenzoate sodium.
This medication contains less than 23 mg of sodium (1 mmol) per ml; it is essentially “sodium-free”.
Follow exactly the administration instructions for this medication as indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
In low doses, Gamavan may be affected by food intake. If you notice that Gamavan is less effective, you must take the medication without food before increasing the dose.
When taking this medication for nocturnal urinary incontinence, reduceto a minimum the consumption of liquidsfrom1hour beforetaking the Gamavan dose anduntil 8hours after.
Treatment of central diabetes insipidus:
Adults and children:Your doctor will prescribe the most suitable dose for your case. Theinitial doserecommended is 0.25ml (90micrograms) three times a day. Subsequently, the doctor will adjust the dose according to the response of each patient. Therecommended daily doseis between 0.5ml (180micrograms) and 3ml (1080micrograms) of Gamavan. Themaintenance dosevaries between 0.25 and 0.5ml (90– 180micrograms) of Gamavan three times a day.
It is essential to note if symptoms of fluid retention in the body and/or decreased sodium in the blood (see section4: Possible adverse effects) appear, in which case the treatment should be interrupted to change the dose.
Nocturnal enuresis primary (nocturnal urinary incontinence) in patients over 5years:
Adults and children:The recommended initial dose is 0.5ml (180micrograms) of Gamavan one hour before bedtime. The dose can be increased up to 1ml (360micrograms) of Gamavan if the initial dose is not sufficient. The need to continue treatment is usually checked every three months by introducing a period without treatment of at least one week.
Instructions for use:
1. Open the bottle (the seal breaks on the first opening).
2. Insert the oral syringe into the dispenser and turn the bottle to fill it with the dose to be administered.
3. Remove the oral syringe from the bottle and check that the syringe bottom presents the correct amount.
4. Place the syringe in the mouth and administer the dose.
5. Rinse with water after each use and close the bottle. Keep the bottle in the outer packaging to protect it from light.
If you take more Gamavan than you should
If you take moreGamavanthan prescribed, contact your doctor or pharmacist immediately.
A overdose may prolong the effect of desmopressin and increase the risk of fluid accumulation in the body or decreased sodium levels in the blood. Symptoms may include headache, nausea, and vomiting, weight gain, and in severe cases, seizures. It is recommended to interrupt treatment, restrict liquid intake, and administer symptomatic treatment if necessary.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone: 91 562 04 20, indicating the medication and the amount ingested.
If you forget to take Gamavan
Do not take a double dose to compensate for the missed doses.
If you interrupt treatment with Gamavan
Do not stop taking Gamavan before completing treatment, as it may not have the expected effect. Only change or interrupt treatment if your doctor indicates it.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
If you experience any of the following symptoms, stop taking Gamavan and consult a doctor or go immediately to a hospital:
Unknown frequency(cannot be estimated from available data)
Inform your doctor or pharmacistif you observe any of these other side effects:
Frequent (can affect up to 1 in 10 people)
Not frequent(can affect up to 1in 100people)
Rare (can affect up to 1 in 1,000 people)
Unknown frequency (cannot be estimated from available data)
Reporting of side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this prospectus. You can also report them directly through the Spanish System for Pharmacovigilance of Medicines for Human Use:www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
This medication does not require special storage conditions.
Store in the original packaging.
After the first opening, store below 25°C for a maximum of 8 weeks.
Do not use this medication after the expiration date that appears on the packaging or label after CAD or EXP. The expiration date is the last day of the month indicated.
Medications should not be disposed of through drains or in the trash. Deposit empty containers and unused medications at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of empty containers and unused medications. By doing so, you will help protect the environment.
Composition of Gamavan
Appearance of the product and contents of the packaging
Gamavan is a transparent solution included in an amber glass bottle sealed with a plastic dispenser, provided with a screw-top also made of plastic. The bottle contains 15 milliliters of solution. The bottle is packaged in a cardboard box with a 1.5 milliliter dosing syringe. The syringe is graduated from 0 to 1.5 milliliters with divisions every 0.1 milliliters. The graduation corresponding to the doses of 0.25 milliliters, 0.5 milliliters, and 1.0 milliliters is specifically marked.
Holder of the marketing authorization
GP-Pharm, S.A.
Industrial Estate Els Vinyets – Els Fogars, sector 2
Carretera Comarcal C244, Km 22,
08777 – Sant Quintí de Mediona (Barcelona) SPAIN
Responsible for manufacturing
Laboratorio Reig Jofré S.A.,
Gran Capitàn nº 10,
08970 Sant Joan Despí – Barcelona
Spain
This medicine is authorized in the member states of the European Economic Area with the following names:
France | NIWINUR 360 microgrammes/ml, oral solution |
Spain | Gamavan 360 microgramos/ml oral solution |
Last review date of this leaflet: May 2021
The detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) http://www.aemps.gob.es/ .
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.